The beat-and-raise quarter with accelerating Life Sciences growth and mid-teens bioprocessing orders supports a bullish read-through for DHR. Traders should watch the Q3 earnings call for further confirmation of bioprocessing recovery and the StatLab acquisition close timeline, which could add high-single-digit core growth to the Diagnostics segment.
Price Chart
Executive Summary
Danaher reported Q2 2026 GAAP EPS of $1.23 (up 60% YoY) and non-GAAP adjusted EPS of $1.94 (up 8% YoY) on revenue of $6.3B (+5.5% YoY). The company raised full-year 2026 adjusted EPS guidance to $8.45-$8.60 from $8.35-$8.55, citing strong Q2 performance and the early completion of the Masimo acquisition. Core revenue growth of 3.0% (4.5% ex-respiratory testing) was driven by a strong quarter in Life Sciences and mid-teens bioprocessing order growth, though Diagnostics core growth was only 2.0% and Biotechnology was 2.5%.
Key Financial Metrics
Key Facts
- Q2 2026 GAAP EPS $1.23 vs $0.77 YoY (+60%)
- Non-GAAP adjusted diluted EPS $1.94 vs $1.80 YoY (+8.0%)
- Revenue $6.265B vs $5.936B YoY (+5.5%)
- Non-GAAP core revenue growth 3.0% YoY; 4.5% ex-respiratory testing
- Operating cash flow $1.534B; free cash flow $1.265B
- Full-year 2026 adjusted EPS guidance raised to $8.45-$8.60 from $8.35-$8.55
- Q3 2026 core revenue guidance: +2.0% to +3.0% YoY
- Full-year 2026 core revenue guidance: +3.0% to +4.0% YoY
- Bioprocessing orders grew mid-teens in Q2
- Announced intent to acquire StatLab (~$250M revenue, >85% recurring, closing by end of 2026)
Financial Impact
GAAP net earnings $870M (up 56.8% YoY); non-GAAP adjusted EPS $1.94 (beat consensus $1.84 by 5.4%); revenue $6.265B (above consensus $6.14B by 2.0%)
Risk Factors
- Core revenue growth of 3.0% remains below pre-pandemic mid-single-digit trends, with Diagnostics core growth at just 2.0%
- Respiratory testing revenue volatility creates a ~1.5% headwind to reported core growth; Q3 guidance implies a 2.5% headwind
- Masimo acquisition integration and associated debt ($10.1B investing cash outflow in Q2) could pressure near-term margins and leverage
- StatLab acquisition (~$250M revenue) is small relative to Danaher's $25B+ annual revenue base and may not materially move the needle
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302830086 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 6w ago | Court Ruling | $202.63 $203.25 | ▲ +0.31% | ▲ +1.83% | $214.57 (+5.89%) |
Jul 21, 2026 10w ago | Press Release | $179.01 $199.58 | ▲ +11.49% | ▲ +8.93% | $214.57 (+19.87%) |
Jul 17, 2026 11w ago | Court Ruling | $203.83 $202.44 | ▼ −0.68% | ▼ −5.13% | $214.57 (+5.27%) |
Jun 26, 2026 14w ago | Court Ruling | $196.19 $192.50 | ▼ −1.88% | ▼ −3.14% | $214.57 (+9.37%) |
Jun 11, 2026 16w ago | ANALYST-UPGRADE | $180.10 $199.05 | ▲ +10.52% | ▲ +8.74% | $214.57 (+19.14%) |
May 27, 2026 18w ago | ANALYST-DOWNGRADE | $172.76 $188.87 | ▼ −9.33% | ▼ −11.62% | $214.57 (−24.21%) |
Apr 23, 2026 23w ago | 424B5 | $177.12 $173.33 | ▼ −2.14% | ▼ −6.16% | $214.57 (+21.15%) |
Apr 22, 2026 23w ago | 424B5 | $184.00 $167.04 | ▼ −9.22% | ▼ −12.38% | $214.57 (+16.62%) |
Apr 17, 2026 24w ago | 8-K | $194.24 $164.54 | ▼ −15.29% | ▼ −20.66% | $214.57 (+10.47%) |
Mar 25, 2026 27w ago | DEFA14A | $186.98 $178.13 | ▼ −4.73% | ▼ −12.59% | $214.57 (+14.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access